Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$133.40 USD

133.40
5,223,540

-1.00 (-0.74%)

Updated Jun 21, 2024 04:00 PM ET

After-Market: $133.32 -0.08 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Is First Trust Multi Cap Value AlphaDEX ETF (FAB) a Strong ETF Right Now?

Smart Beta ETF report for FAB

Biotech Stock Roundup: REGN Down on Eylea Data, CINC Surges on AZN Offer & More

Updates from Regeneron (REGN) and CinCor Pharma (CINC) are the key highlights from the biotech sector during the past week.

Moderna (MRNA) Reports 2023 Business View & Pipeline Updates

Moderna (MRNA) expects to record a minimum of $5 billion in revenues from COVID vaccine sales in 2023. It also expects to incur around $4.5 billion as R&D expenses in 2023.

Novavax (NVAX) Names John Jacobs as New CEO, Shares Rise

Novavax (NVAX) appoints John C. Jacobs as its new president and chief executive officer, effective Jan 23, 2023.

The Zacks Analyst Blog Highlights Thermo Fisher Scientific, Starbucks, Moderna, Canadian Pacific Railway and Micron Technology

Thermo Fisher Scientific, Starbucks, Moderna, Canadian Pacific Railway and Micron Technology are included in this Analyst Blog.

Moderna (MRNA) Gains As Market Dips: What You Should Know

Moderna (MRNA) closed the most recent trading day at $183.95, moving +2% from the previous trading session.

Sheraz Mian headshot

Top Stock Reports for Thermo Fisher Scientific, Starbucks & Moderna

Today's Research Daily features new research reports on 16 major stocks, including Thermo Fisher Scientific Inc. (TMO), Starbucks Corporation (SBUX) and Moderna, Inc. (MRNA).

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH

CytomX (CTMX) Up 55% on Strategic Partnership With Moderna

CytomX (CTMX) inks an agreement with Moderna to develop therapeutics for oncology and non-oncology conditions. The company also provides its business outlook for 2023.

Moderna (MRNA) to Boost mRNA Portfolio With OriCiro Buyout

Moderna (MRNA) inks an agreement to acquire OriCiro for $85 million. The acquisition is expected to expand and boost Moderna's mRNA manufacturing capabilities.

Are Options Traders Betting on a Big Move in Moderna (MRNA) Stock?

Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.

Novavax (NVAX) Starts A New Study on COVID-Flu Combo Jab

Novavax (NVAX) initiates a mid-stage study evaluating its COVID-19-Influenza combination and standalone influenza vaccines in adults aged 50 through 80 years.

Moderna (MRNA) Gains As Market Dips: What You Should Know

Moderna (MRNA) closed the most recent trading day at $179.62, moving +0.42% from the previous trading session.

Andrew Rocco headshot

Biotech: 3 Profitable Bios Worth Owning

The biotechnology space can be a difficult area to generate profits. Drugs take years to develop and often fail FDA approval. Today we will look at three top biotech stocks that are very profitable and have attractive future prospects.

Andrew Rocco headshot

Biotech is Set for a Blockbuster 2023: Here's Why

The biotech sector has been outperforming the major U.S. indices for the past few months. Can the strength continue?

Stock Market News for Dec 21, 2022

Wall Street closed higher on Tuesday terminating a four-day losing streak.

Moderna's (MRNA) BA.1 Omicron Booster Gets CHMP Nod for Kids

The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.1 subvariant, for young children aged between six and 11 years.

Stock Market News for Dec 19, 2022

U.S. stock markets closed sharply lower On Friday as market participants remained concerned about a recession in 2023.

Kinjel Shah headshot

Pharma Stock Roundup: LLY's 2023 View, MRK-MRNA Joint Cancer Vaccine Data & More

Eli Lilly (LLY) gives its financial guidance for 2023. Merck (MRK) and Moderna's (MRNA) mRNA-based cancer vaccine shows positive results in a joint study.

Company News for Dec 15, 2022

Companies in The News Are:BRZE,DAL,MRNA,MRK,SOFI

Moderna (MRNA) Up 20% on Upbeat Data From Cancer Jab Study

Data from a mid-stage study showed that Moderna's (MRNA) personalized cancer vaccine candidate combined with Merck's Keytruda reduces the risk of recurrence/death by 44% in melanoma patients.

Andrew Rocco headshot

Trending Today: 5 Stocks in the News

So far this week, several stocks have had headline-driven catalysts. We will cover 5 stocks trending in the news.

Vertex (VRTX) to Start Clinical Study on mRNA-based CF Therapy

Following clearance of the IND application by the FDA, Vertex (VRTX) intends to start a clinical study evaluating a single ascending dose of VX-522 in cystic fibrosis patients in the coming weeks.

Mark Vickery headshot

Top Stock Reports for JPMorgan, Intel & Advanced Micro Devices

Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Intel Corporation (INTC) and Advanced Micro Devices, Inc. (AMD).